Reply to thread

There are no marketed drugs that came from  AME yet. There are a few in development but none looks that promising. Both AME and Imclone are shaping up as epic failures on Lilly's part. Sales of Erbitux have remained modest and the pipeline from Imclone looks equally iffy as that originating from AME. Bottom line: biotechnology will not save LLY from itself. Yes it really is that dire a situation in the long run.


And regarding TB - Xigris - enough said. Pathetic legacy, perhaps only good  when compared to the likes of SP http://www.cafepharma.com/boards/images/icons/lol.gif